BLX-1002 Restores Glucose Sensitivity and Enhances Insulin Secretion Stimulated by GLP-1 and Sulfonylurea in Type 2 Diabetic Pancreatic Islets

Overview

Journal Physiol Rep

Specialty Physiology

Date 2014 May 30

PMID 24872354

Authors

Qimin Zhang

Fan Zhang

Ake Sjoholm

Affiliations

Soon will be listed here.

Abstract

BLX-1002 is a novel thiazolidinedione with no peroxisome proliferator-activated receptor (PPAR) activity that has been shown to improve glycemia in type 2 diabetes without weight gain. We previously found that BLX-1002 selectively augments glucose-sensitive (but not basal) insulin secretion in normal mouse β-cells. We have now extended these observations to other insulin secretagogues and to diabetic rat islets. To this end, dynamics of insulin secretion stimulated by glucose, GLP-1, and the sulfonylurea tolbutamide were examined in pancreatic islets from nondiabetic Wistar and type 2 diabetic Goto-Kakizaki rats ex vivo. BLX-1002 restored normal glucose-sensitive insulin secretion in otherwise "glucose-blind" islets from GK rats, but did not affect basal or glucose-stimulated secretion in normal Wistar rat islets. The stimulatory effect of BLX-1002 on insulin secretion at high glucose required Ca(2+) and involved phosphatidylinositol 3-kinase (PI3K) activity. Consistent with its effects on insulin secretion, BLX-1002 also augmented insulin secretion and cytoplasmic-free Ca(2+) concentrations ([Ca(2+)]i) stimulated by high glucose, GLP-1, and tolbutamide in islets from GK, but not Wistar, rats. The inactive analog BLX-1237 had no effects. In conclusion, our findings suggest that BLX-1002 potentiates insulin secretion by different stimuli in diabetic β-cells only, in a Ca(2+)-dependent manner and involving PI3K.

References

Zhang F, Dey D, Branstrom R, Forsberg L, Lu M, Zhang Q . BLX-1002, a novel thiazolidinedione with no PPAR affinity, stimulates AMP-activated protein kinase activity, raises cytosolic Ca2+, and enhances glucose-stimulated insulin secretion in a PI3K-dependent manner. Am J Physiol Cell Physiol. 2008; 296(2):C346-54. DOI: 10.1152/ajpcell.00444.2008. View

De Camilli P, Emr S, McPherson P, Novick P . Phosphoinositides as regulators in membrane traffic. Science. 1996; 271(5255):1533-9. DOI: 10.1126/science.271.5255.1533. View

Malaisse W . The beta cell in NIDDM: giving light to the blind. Diabetologia. 1994; 37 Suppl 2:S36-42. DOI: 10.1007/BF00400824. View

Rameh L, Cantley L . The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem. 1999; 274(13):8347-50. DOI: 10.1074/jbc.274.13.8347. View

Holz 4th G, Kuhtreiber W, Habener J . Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature. 1993; 361(6410):362-5. PMC: 2916679. DOI: 10.1038/361362a0. View

. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013; 36(4):1033-46. PMC: 3609540. DOI: 10.2337/dc12-2625. View

Porte Jr D, Kahn S . beta-cell dysfunction and failure in type 2 diabetes: potential mechanisms. Diabetes. 2001; 50 Suppl 1:S160-3. DOI: 10.2337/diabetes.50.2007.s160. View

Pfeifer M, Halter J, Porte Jr D . Insulin secretion in diabetes mellitus. Am J Med. 1981; 70(3):579-88. DOI: 10.1016/0002-9343(81)90579-9. View

Selway J, Moore C, Mistry R, Challiss R, Herbert T . Molecular mechanisms of muscarinic acetylcholine receptor-stimulated increase in cytosolic free Ca(2+) concentration and ERK1/2 activation in the MIN6 pancreatic β-cell line. Acta Diabetol. 2011; 49(4):277-89. PMC: 3407357. DOI: 10.1007/s00592-011-0314-9. View

10.

Ghanaat-Pour H, Huang Z, Lehtihet M, Sjoholm A . Global expression profiling of glucose-regulated genes in pancreatic islets of spontaneously diabetic Goto-Kakizaki rats. J Mol Endocrinol. 2007; 39(2):135-50. DOI: 10.1677/JME-07-0002. View

11.

Zeender E, Maedler K, Bosco D, Berney T, Donath M, Halban P . Pioglitazone and sodium salicylate protect human beta-cells against apoptosis and impaired function induced by glucose and interleukin-1beta. J Clin Endocrinol Metab. 2004; 89(10):5059-66. DOI: 10.1210/jc.2004-0446. View

12.

Wollheim C, SHARP G . Regulation of insulin release by calcium. Physiol Rev. 1981; 61(4):914-73. DOI: 10.1152/physrev.1981.61.4.914. View

13.

. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes. 1995; 44(11):1249-58. View

14.

Weir G . Which comes first in non-insulin-dependent diabetes mellitus: insulin resistance or beta-cell failure? Both come first. JAMA. 1995; 273(23):1878-9. View

15.

Hussain S, Mansouri S, Sjoholm A, Patrone C, Darsalia V . Evidence for cortical neuronal loss in male type 2 diabetic Goto-Kakizaki rats. J Alzheimers Dis. 2014; 41(2):551-60. DOI: 10.3233/JAD-131958. View

16.

Zimmet P, Alberti K, Shaw J . Global and societal implications of the diabetes epidemic. Nature. 2001; 414(6865):782-7. DOI: 10.1038/414782a. View

17.

Tourrel C, Bailbe D, Meile M, Kergoat M, Portha B . Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes. 2001; 50(7):1562-70. DOI: 10.2337/diabetes.50.7.1562. View

18.

Eto K, Yamashita T, Tsubamoto Y, Terauchi Y, Hirose K, Kubota N . Phosphatidylinositol 3-kinase suppresses glucose-stimulated insulin secretion by affecting post-cytosolic [Ca(2+)] elevation signals. Diabetes. 2002; 51(1):87-97. DOI: 10.2337/diabetes.51.1.87. View

19.

Kolic J, Spigelman A, Plummer G, Leung E, Hajmrle C, Kin T . Distinct and opposing roles for the phosphatidylinositol 3-OH kinase catalytic subunits p110α and p110β in the regulation of insulin secretion from rodent and human beta cells. Diabetologia. 2013; 56(6):1339-49. DOI: 10.1007/s00125-013-2882-4. View

20.

Virkamaki A, Ueki K, Kahn C . Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest. 1999; 103(7):931-43. PMC: 408269. DOI: 10.1172/JCI6609. View